Virax Biolabs expands Ebola immunology portfolio
It is developing a peptide pool for the Bundibugyo strain and offers one for the Zaire strain.
See the latest news and media coverage for Virax Biolabs. We track all announcements, press releases, and industry mentions in real time, all in one place.
Immunology research company
viraxbiolabs.comLast updated
In short: Virax Biolabs focused on its ViraxImmune platform for post-acute infection syndromes and secured $5 million in private placement funding.
It is developing a peptide pool for the Bundibugyo strain and offers one for the Zaire strain.
The certifications support regulated IVD development and U.S. clinical validation for its PAIS strategy.
The offering of 12.5M shares at $0.40 each will provide working capital. H.C. Wainwright acted as placement agent.
The ViraxImmune assay targets T cell dysfunction in post-acute infection syndromes, with a US study planned for 2026.
Virax Biolabs Group Limited VRAX shares are trending on Tuesday. VRAX shares rose 17.36% to $0.28 in after-hours trading on Monday. The jump in the...
Detailed price information for Virax Biolabs Group Limited (VRAX-Q) from The Globe and Mail including charting and trades.
VRAX shares fell 12.79% in after-hours trading following a $5 million private placement announcement.
Virax Biolabs (VRAX) has delivered a -87.0400% change over the past year, with a 52-week range between 0.1000 and 1.1900. What Is the Average Daily...
Track Virax Biolabs and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Virax Biolabs and other trending companies.